SCHEMBL25863926

SCHEMBL25863926

CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4C3CC[C@@]21CC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.79
▸ LMNA P02545 5/20 0.79
▸ AR P10275 5/20 0.79
▸ CYP3A4 P08684 4/20 0.79
▸ SLC6A4 P31645 4/20 0.79
▸ ESR1 P03372 4/20 0.79
▸ SHBG P04278 4/20 0.79
▸ ABCB11 O95342 3/20 0.79
▸ MEN1 O00255 2/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ NR3C1 P04150 2/20 0.79
▸ CYP2C19 P33261 2/20 0.79
▸ POLB P06746 1/20 0.79
▸ NR3C2 P08235 1/20 0.60
▸ NR1I2 O75469 1/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ TSHR P16473 1/20 0.59
▸ HIF1A Q16665 1/20 0.59
▸ ADRA2A P08913 1/20 0.59
▸ OPRM1 P35372 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11868140 1.00 PGR (0.79) PGRLMNAARCYP3A4SLC6A4
SCHEMBL25863862 1.00 PGR (0.79) PGRLMNAARCYP3A4SLC6A4
SCHEMBL11859369 0.92 PGR (0.67) PGRLMNAARCYP3A4SLC6A4
SCHEMBL11858281 0.91 PGR (0.78) PGRLMNAARCYP3A4SLC6A4
SCHEMBL10930932 0.91 PGR (0.78) PGRLMNAARCYP3A4SLC6A4
SCHEMBL10929203 0.91 PGR (0.78) PGRLMNAARCYP3A4SLC6A4
SCHEMBL1843682 0.91 PGR (0.78) PGRLMNAARCYP3A4SLC6A4
Norgestrel SCHEMBL4319113 0.88 PGR (1.00) PGRLMNAARCYP3A4SLC6A4
Levonorgestrel SCHEMBL21741985 0.88 PGR (1.00) PGRLMNAARCYP3A4SLC6A4
Levonorgestrel SCHEMBL691861 0.88 PGR (1.00) PGRLMNAARCYP3A4SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME SHBG, CYP19A1, GNRHR PGR 16/4885LMNA 388/4885AR 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback